Trial Profile
A Study of Evaluating Recombinant Human Anti-EGFR Monoclonal Antibody (SCT200) for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma After Failure of Platinum-based Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2022
Price :
$35
*
At a glance
- Drugs SCT 200 (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Sinocelltech
- 03 Feb 2020 Planned End Date changed from 28 Feb 2020 to 28 May 2020.
- 03 Feb 2020 Planned primary completion date changed from 31 May 2019 to 29 Feb 2020.
- 03 Feb 2020 Status changed from not yet recruiting to active, no longer recruiting.